Relugolix — Active Pharmaceutical Ingredient

Relugolix is an active pharmaceutical ingredient found in 2 FDA-approved drug products. Forms: TABLET. Routes: ORAL.

Drug Ingredients A–Z 1 min read
This content is for informational purposes only. Always consult a healthcare professional.

Relugolix (2 brand names, 1 dosage form, 1 route)

Available dosage forms: TABLET.

Routes of administration: ORAL.

Brand Names

  • MYFEMBREE
  • ORGOVYX

Indications and Usage

ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.

Contraindications

ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.

Adverse Reactions

The following clinically significant adverse reactions are described elsewhere in the labeling: QT/QTc Interval Prolongation [see Warnings and Precautions (5.1)].

Mechanism of Action

Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.